Serum Indices (HIL)
[Serum Indices (HIL)]
EPTIS factsheet 1616092 | Last revision 2026-09-24 | URL: https://www.eptis.bam.de/pts1616092 https://www.eptis.bam.de/pts1616092
| PT provider | ||||||||||||||||||||||||||||
| PT provider | Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust | |||||||||||||||||||||||||||
| Based in | United Kingdom | |||||||||||||||||||||||||||
| Language(s) | English | |||||||||||||||||||||||||||
| Remarks | Provides EQA coverage for serum indices: haemolysis (H), icterus (I) and lipaemia (L), both for quantitive and category data. Analyte X is a unique element of the Scheme that looks at the impact of the HIL in the specimen on a particular analyte. The Scheme also collects and presents data on the current HIL cut-off that is in use by participating laboratories for Analyte X. The aim of this is to build up a library of the current variation in practice and provide laboratories with evidence of what they are doing compared to other users of the same method and other methods. Analyte X will change from distribution to distribution, please report in your usual units. Analyte X may be a Chemistry analyte or an Immunoassay analyte. | |||||||||||||||||||||||||||
| Keywords | ||||||||||||||||||||||||||||
| Product groups |
Health care / medical devices
|
|||||||||||||||||||||||||||
| Testing fields |
Medical analysis
|
|||||||||||||||||||||||||||
| Technical details | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Aims of the PT scheme | ||||||||||||||||||||||||||||
| Target group of participants | Clinical Chemistry Public & Private Labs | |||||||||||||||||||||||||||
| Linked to specific legislation / standards | ISO/IEC 17043:2023 | |||||||||||||||||||||||||||
| Additional, subsidiary aims | Post market surveillance of testing methods | |||||||||||||||||||||||||||
| Number of participants | ||||||||||||||||||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043:2023 |
|||||||||||||||||||||||||||
| Operation is commissioned / requested by | ||||||||||||||||||||||||||||
| Fees and frequency | ||||||||||||||||||||||||||||
| Participation fee | Contact provider for current fee, which depends on location and extent of service required. | |||||||||||||||||||||||||||
| Regularly operated | Yes (Monthly (11 per year)) | |||||||||||||||||||||||||||
| Year of first operation | 2015 | |||||||||||||||||||||||||||
| Contact details of the PT provider | ||||||||||||||||||||||||||||
| Provider | Contact person | |||||||||||||||||||||||||||
|
Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Medical Centre P O Box 3909 B15 2SQ Birmingham United Kingdom Phone: +44 121 414 7300 Fax: Web: https://www.birminghamquality.org.uk https://www.birminghamquality.org.uk |
Birmingham Quality
Phone: +44 121 414 7300 Fax: Email: birminghamquality@uhb.nhs.uk birminghamquality@uhb.nhs.uk |
|||||||||||||||||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.